Method for purifying human coagulation factor VIIa

Through a three-step chromatography process (anion exchange chromatography, anion exchange chromatography and hydrophobic chromatography), combining virus inactivation and virus removal filtration, the problems of high purification cost and safety risks of human coagulation factor VIIa in the prior art are solved. High purity and safety preparation is achieved, simplifying the process and reducing costs.

CN111849945BActive Publication Date: 2024-11-29CHIA TAI TIANQING PHARMA GRP CO LTD +2
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202010330060.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-04-24
Publication Date
2024-11-29
Estimated Expiration
2040-04-24

AI Technical Summary

Technical Problem

The existing human coagulation factor VIIa purification technology is costly, the immune affinity chromatography has safety risks and the process is complex, making it difficult to effectively remove impurities such as Gla variants, polymers, oxides and degradants.

Method used

Three-step chromatography technology is adopted: anion exchange chromatography, anion exchange chromatography and hydrophobic chromatography, combined with virus inactivation and virus removal filtration, avoiding the affinity chromatography step, and removing impurities through two-step anion exchange and hydrophobic chromatography. Reduce industrialization costs and improve purity and safety.

Benefits of technology

The preparation of human coagulation factor VIIa with high purity, activity and safety is achieved, which reduces industrialization costs, avoids the risk of anti-FVIIa antibodies falling off, simplifies the process and is easy to amplify production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002464622730000071
    Figure BDA0002464622730000071
  • Figure BDA0002464622730000081
    Figure BDA0002464622730000081
  • Figure BDA0002464622730000082
    Figure BDA0002464622730000082
Patent Text Reader

Abstract

The present invention provides a method for purifying human coagulation factor VIIa, which adopts three-step purification of anion exchange chromatography, anion exchange chromatography and hydrophobic chromatography, as well as virus inactivation and virus removal filtration steps to prepare human coagulation factor VIIa whose purity, activity and safety meet the requirements for pharmaceutical use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a method for purifying human coagulation factor VIIa. Background Art

[0002] Human coagulation factor VII (FVII) is a vitamin K-dependent serine protease that can initiate the extrinsic coagulation pathway or participate in the intrinsic coagulation pathway by activating human coagulation factor IX. FVII is synthesized in the liver and secreted into the blood, circulating in the blood as a single-chain glycoprotein (zymogen) with a molecular weight of approximately 50,000 Da. The FVII zymogen is hydrolyzed by protease at site R152-I153 to generate a double-chain molecule connected by a disulfide bond, thereby converting to the active form FVIIa. Clinical studies have shown that FVIIa has a satisfactory therapeutic effect on hemostasis of thrombocytopenia and platelet dysfunction, severe trauma, and large-area surgical operations.

[0003] Early human coagulation factor VII preparations were made from fresh frozen plasma, adsorbed by barium sulfate and purified by multiple steps of chromatography. With the application of DEAE-Sephadex A-50 gel, it gradually changed to A-50 gel adsorption as the main method and purified by multiple steps of chromatography. Since the content of human coagulation factor VII in plasma is extremely low, usually 200-400 ng / ml, the preparation of human coagulation factor VII is very difficult and the cost is extremely high. At the same time, the plasma extraction and preparation process is complicated, the batch-to-batch differences are large, and the stability is poor. In addition, using plasma as a raw material greatly increases the risk of infection by exogenous viruses. In recent years, the development of genetic engineering technology has made it possible to prepare FVII recombinantly in vitro. NovoSeven of Novo Nordisk of Denmark is a recombinant human coagulation factor VIIa with biological activity obtained by introducing the cDNA gene of human coagulation factor VII into BHK cells (baby hamster kidney cells) through genetic engineering technology, and then activated and highly purified.

[0004] Tomokiyo et al. reported a purification method for preparing human coagulation factor VIIa from plasma (Tomokiyo K, Yano H, Imamura M, et al. Large-scale production and properties of human plasma-derived activated Factor VII concentrate [J]. Vox Sanguinis, 2010, 84 (1): 54-64.), the specific steps of which include: using Q-Sepharose Fast Flow to capture FVII from plasma, then using immunoaffinity chromatography of anti-FVII antibodies, and then using DEAE-Sepharose to purify after virus removal to obtain a FVII-FVIIa mixture, and then obtaining FVIIa by an in-solution activation method. Finally, the FVIIa preparation is obtained by dialysis, preparation filling, freeze drying and other steps.

[0005] Jurlander et al. disclosed Novo Nordisk's downstream purification process for FVIIa (Jurlander B, Thiml, Klausen NK, et al. Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development [J]. Seminars in Thrombosis and Hemostasis, 2001, 27 (4): 373-384.): After the cell culture fluid is harvested, the first step is anion exchange chromatography to capture FVII, followed by virus inactivation and immunoaffinity chromatography, and then two more steps of anion exchange chromatography to produce fully activated FVIIa.

[0006] CN1121723A discloses adding Zn in the purification chromatography process. 2+ FVII is subjected to controlled activation and degradation, and the chromatographic steps are: anion exchange, immunoaffinity, anion exchange, anion exchange.

[0007] CN101268185A discloses that a hydrophobic chromatography process is added during the purification process to control product-related impurities in drugs, such as different levels of N-linked glycosylation variants, oxidized forms, proteolytic degradation forms (heavy chain cleavage forms) and aggregates contained in the late elution peak.

[0008] The existing downstream purification technology of human coagulation factor FVIIa usually adds an affinity chromatography step to specifically capture the FVIIa protein through a chromatography medium connected with a FVIIa antibody, but this technology has the following disadvantages: ① high industrialization cost, and ② the shedding of the immunoaffinity chromatography ligand will cause related safety risks. Summary of the invention

[0009] The object of the present invention is at least to provide an improved purification process of human coagulation factor VIIa.

[0010] In some embodiments, the present invention provides a method for purifying human coagulation factor VIIa, which comprises the following steps: anion exchange chromatography, anion exchange chromatography, and hydrophobic chromatography.

[0011] In some embodiments, the present invention provides a method for purifying human coagulation factor VIIa, which comprises the following steps: anion exchange chromatography, anion exchange chromatography, hydrophobic chromatography, and each step is performed sequentially.

[0012] In some embodiments, the present invention provides a method for purifying human coagulation factor VIIa, comprising the following steps performed in sequence:

[0013] 1) Anion exchange chromatography;

[0014] 2) Inactivation of viruses;

[0015] 3) anion exchange chromatography;

[0016] 4) Hydrophobic chromatography;

[0017] 5) Virus removal filtration;

[0018] 6) Ultrafiltration fluid replacement;

[0019] 7) Sterile filtration to obtain the stock solution.

[0020] In some embodiments, the present invention provides a method for purifying human coagulation factor VIIa, comprising the following steps performed in sequence:

[0021] 1) Anion exchange chromatography;

[0022] 2) performing virus inactivation on the product obtained in step 1);

[0023] 3) further purifying the product obtained in step 2) by anion exchange chromatography;

[0024] 4) further purifying the product obtained in step 3) by hydrophobic chromatography;

[0025] 5) filtering the product obtained in step 4) to remove viruses;

[0026] 6) ultrafiltration of the product obtained in step 5) to replace the liquid;

[0027] 7) The product obtained in step 6) is sterilized and filtered to obtain a stock solution.

[0028] In some embodiments, the present invention first uses anion exchange chromatography to capture the target protein from the cell harvest fluid, wherein the anion exchange chromatography optionally includes (a) equilibrating the anion exchange material with an equilibration buffer, (b) eluting the anion exchange material with a wash buffer, and (c) eluting the anion exchange material with an elution buffer, wherein the equilibration buffer has a pH of 6-10, preferably a pH of about 8, and contains sodium chloride at a concentration of at least about 50 mM, preferably a sodium chloride concentration of about 50 mM; the wash buffer has a pH of 6-10, preferably a pH of about 8, and optionally contains sodium chloride at a concentration of at least about 50 mM; the elution buffer has a pH of 6-10, preferably a pH of about 8, and contains sodium chloride at a concentration of 50-800 mM, preferably a sodium chloride concentration of about 500 mM.

[0029] In some aspects, the first anion exchange chromatography step of the present invention comprises equilibrating the anion exchange material with an equilibration buffer and eluting the anion exchange material with an elution buffer, wherein the equilibration buffer has a pH of 6-10, preferably a pH of about 8, and comprises sodium chloride at a concentration of at least about 50 mM, preferably a sodium chloride concentration of about 50 mM; and the elution buffer has a pH of 6-10, preferably a pH of about 8, and comprises sodium chloride at a concentration of 50-800 mM, preferably a sodium chloride concentration of about 500 mM.

[0030] In some aspects, the first step of anion exchange chromatography of the present invention comprises balancing the anion exchange material with an equilibration buffer and eluting the anion exchange material with an elution buffer, wherein the equilibration buffer and the elution buffer can be independently selected from phosphate buffer, tris(hydroxymethyl)aminomethane-hydrochloric acid buffer, 4-hydroxyethylpiperazineethanesulfonic acid buffer, N-tris(hydroxymethyl)methylglycine buffer, N,N-dihydroxyethylglycine buffer, preferably the equilibration buffer and the elution buffer are phosphate buffers, and most preferably the equilibration buffer and the elution buffer each comprise about 20 mmol / L of phosphate.

[0031] In some embodiments, the virus inactivation of the eluate obtained from the first anion exchange chromatography step is performed using a S / D (surfactant / detergent) method.

[0032] In some embodiments, the virus inactivated product is subjected to a second anion exchange chromatography to remove Gla (γ-carboxyglutamate) deletion / partial deletion variants and other related impurities, wherein the anion exchange chromatography step optionally includes (a) equilibrating the anion exchange material with an equilibration buffer, (b) eluting the anion exchange material with a washing buffer, and (c) eluting the anion exchange material with an elution buffer, wherein the equilibration buffer has a pH of 6-10, preferably a pH of about 8, and contains a chloride concentration of at least about 50 mM. The washing buffer has a pH of 6-10, preferably a pH of about 8, and comprises a sodium chloride concentration of at least about 50 mM and / or a calcium chloride concentration of at least about 1 mM, preferably comprises about 100 mM sodium chloride and about 2.25 mM calcium chloride; the elution buffer has a pH of 6-10, preferably a pH of about 8, and comprises a sodium chloride concentration of at least about 50 mM and / or a calcium chloride concentration of at least about 1 mM, preferably comprises about 100 mM sodium chloride and about 5 mM calcium chloride.

[0033] In some aspects, the second anion exchange chromatography of the present invention comprises (a) equilibrating the anion exchange material with an equilibration buffer, (b) eluting the anion exchange material with a wash buffer, and (c) eluting the anion exchange material with an elution buffer, wherein the equilibration buffer has a pH of 6-10, preferably a pH of about 8, and comprises sodium chloride at a concentration of at least about 50 mM, preferably about 100 mM sodium chloride; the wash buffer has a pH of 6-10, preferably a pH of about 8, and comprises sodium chloride at a concentration of at least about 50 mM and / or calcium chloride at a concentration of at least about 1 mM, preferably about 100 mM sodium chloride and about 2.25 mM calcium chloride; the elution buffer has a pH of 6-10, preferably a pH of about 8, and comprises sodium chloride at a concentration of at least about 50 mM and / or calcium chloride at a concentration of at least about 1 mM, preferably about 100 mM sodium chloride and about 5 mM calcium chloride.

[0034] In some aspects, the second step anion exchange chromatography of the present invention comprises balancing the anion exchange material with an equilibrium buffer, eluting the anion exchange material with a washing buffer, and eluting the anion exchange material with an elution buffer, wherein the equilibrium buffer, the washing buffer, and the elution buffer can be independently selected from phosphate buffer, tris(hydroxymethyl)aminomethane-hydrochloric acid buffer, 4-hydroxyethylpiperazineethanesulfonic acid buffer, N-tris(hydroxymethyl)methylglycine buffer, N,N-dihydroxyethylglycine buffer, preferably the equilibrium buffer, the washing buffer, and the elution buffer are tris(hydroxymethyl)aminomethane buffer, respectively, and most preferably the equilibrium buffer, the washing buffer, and the elution buffer respectively include about 10 mmol / L tris(hydroxymethyl)aminomethane-hydrochloric acid.

[0035] In some embodiments, the eluate obtained from the second anion exchange chromatography is further subjected to hydrophobic chromatography to remove product-related impurities such as polymers, oxides and degradation products. The hydrophobic chromatography step may optionally include (a) equilibrating the hydrophobic interaction chromatography material with an equilibration buffer, (b) eluting the hydrophobic interaction chromatography material with an elution buffer, and (c) eluting the hydrophobic interaction chromatography material with an elution buffer, wherein the loading solution of this chromatography step contains salt and / or zwitterions, and the salt may be selected from the group consisting of ammonium acetate, ammonium sulfate, ammonium chloride, sodium chloride, sodium acetate, sodium sulfate, potassium acetate, potassium chloride and potassium sulfate, and the zwitterions may be selected from the group consisting of glycine, alanine, leucine and isoleucine, preferably ammonium acetate.

[0036] In some embodiments, the hydrophobic chromatography of the present invention comprises balancing the hydrophobic interaction chromatography material with an equilibration buffer and eluting the hydrophobic interaction chromatography material with an elution buffer, wherein the equilibration buffer comprises 10-30 mmol / L of glycylglycine, preferably about 10 mmol / L of glycylglycine, and 1-20 mol / L of ammonium acetate, preferably about 1.8 mol / L of ammonium acetate, and the pH of the equilibration buffer is 6-10, preferably the pH is about 6; the elution buffer comprises 10-30 mmol / L of glycylglycine, preferably about 10 mmol / L of glycylglycine, and 10-100 mmol / L of trisodium citrate dihydrate, preferably about 30 mmol / L of trisodium citrate dihydrate, and the pH of the elution buffer is 6-10, preferably the pH is about 6.

[0037] In some embodiments, the hydrophobic chromatography eluate product is subjected to virus removal filtration, and then ultrafiltration, liquid exchange and sterilization filtration are performed to obtain the stock solution.

[0038] In some embodiments, the method for purifying human coagulation factor VIIa provided by the present invention does not include an affinity chromatography step.

[0039] In some embodiments, the method for purifying human Factor VIIa provided by the present invention does not contain an immunoaffinity chromatography step of coupling Factor VIIa antibodies to an affinity chromatography medium.

[0040] In some embodiments, the present invention provides a method for purifying human coagulation factor VIIa, wherein the human coagulation factor VIIa is a recombinant human coagulation factor VIIa produced under cell culture conditions. In some specific embodiments, the human coagulation factor VIIa of the present invention is not a human coagulation factor VIIa derived from plasma.

[0041] The purpose of the present invention is also to provide a method for reducing Gla variants in human coagulation factor VIIa, which method comprises performing the following steps in sequence: anion exchange chromatography, anion exchange chromatography, and hydrophobic chromatography. In some specific embodiments, the human coagulation factor VIIa is recombinant human coagulation factor VIIa. In other specific embodiments, the method does not include affinity chromatography.

[0042] The present invention also aims to provide a method for reducing the content of polymers, degradation products and oxides in a recombinant protein. In some specific embodiments, the recombinant protein is recombinant human coagulation factor VIIa.

[0043] In some embodiments of the present invention, the purification of recombinant human coagulation factor VIIa excludes the step of affinity chromatography. In the immunoaffinity chromatography step, the antibody protein coupled to the affinity filler may contaminate or interfere with the purified product. The present invention excludes affinity chromatography, which can avoid the risk of anti-FVIIa antibody shedding, thereby obtaining a recombinant protein product with higher purity and less immunogenicity.

[0044] The purification method of human coagulation factor VIIa provided by the present invention has the following beneficial effects: two steps of anion exchange plus one step of hydrophobic chromatography, a total of three steps of chromatography, can be used to prepare human coagulation factor VIIa with purity, activity and safety that meet the requirements of pharmaceutical use, and the other two steps of virus inactivation and virus removal filtration process can ensure that the risk of virus contamination of the final product is eliminated. The method of the present invention does not contain an immunoaffinity chromatography step, has a low industrialization cost and avoids the risk of anti-FVIIa antibody shedding; in addition, the three-step chromatography process is simple and easy to scale up for production.

[0045] Explanation and Definitions

[0046] For the purposes of this application, unless otherwise stated, the following terms used in the specification and claims shall have the following meanings.

[0047] "Coagulation factors" refers to various protein components involved in the blood coagulation process, including coagulation factors I, II, III, IV, V, VII, VIII, IX, X, XI, XII, and XIII.

[0048] "Recombinant human coagulation factor": a human coagulation factor produced by recombinant DNA technology or recombinant RNA technology. Recombinant protein is obtained by applying gene recombination technology to obtain a recombinant vector connected to a gene fragment that can be translated into the target protein, which is then transferred into a host cell that can express the target protein to express a specific recombinant protein molecule. The production of recombinant proteins currently includes four major systems: prokaryotic expression system, mammalian cell expression system, eukaryotic expression system and insect cell expression system.

[0049] "Antibody": Used in the broadest sense, specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies (eg, bispecific antibodies), and antibody fragments so long as they possess the desired biological activity.

[0050] "Gla (γ-carboxyglutamate) deletion / partial deletion variant": Natural human coagulation factor VII undergoes post-translational modification, including carboxylation dependent on microbial K, resulting in 10 Gla (γ-carboxyglutamate) residues at the N-terminus of FVII or FVIIa. FVIIa produced by genetic recombinant technology is prone to form variants with varying degrees of Gla during expression, which are called Gla (γ-carboxyglutamate) deletion / partial deletion variants, among which the higher the Gla (γ-carboxyglutamate) modification ratio, the higher the specific activity of the protein.

[0051] "Affinity chromatography" refers to a purification and extraction method that combines chromatography technology with the specific reaction of antigens and antibodies. The usual practice is to chemically bind antibodies (or antigens) to a column material with molecular sieve function such as agarose and dextran. When the extract passes through the affinity chromatography column, it binds to the corresponding antigen (antibody) on the column material.

[0052] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be construed in an open and non-exclusive sense, ie, "including but not limited to".

[0053] Unless otherwise stated, "about" in the present invention means fluctuations within the range of ±5% of the given specific numerical range, preferably within the range of ±2%, and more preferably within the range of ±1%. For example, a pH value of about 5.5 means a pH of 5.5±5%, preferably a pH of 5.5±2%, and more preferably a pH of 5.5±1%.

[0054] The term "polymer" as used herein refers to a polymer produced by the aggregation of recombinant proteins due to the interaction of amino acid residues on the peptide chain or the hydrophobic or electrostatic effects between molecules.

[0055] The term "degradation product" as used herein refers to a product with a smaller molecular weight than the recombinant protein, which is produced by reactions such as deamidation or peptide chain cleavage of the recombinant protein in aqueous solution. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1The second step anion exchange chromatography is used to remove the GLa (γ-carboxyglutamic acid) deletion / partial deletion variant (determined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)). Lane 1 is the loading solution, lane 2 is the flow-through solution, lane 3 is the elution peak 1, lane 4 is the elution peak 2, lane 5 is the elution peak, and M is a molecular weight marker. DETAILED DESCRIPTION

[0057] Example 1 Purification of FVIIa

[0058] Downstream purification of FVIIa is performed in seven steps:

[0059] The first step is anion exchange chromatography.

[0060] The clarified cell culture fluid containing FVIIa was loaded onto a TMAE anion chromatography column pre-equilibrated with buffer A1 (20 mmol / L sodium hydrogen phosphate hydrate, 50 mmol / L sodium chloride, pH 8.0-8.2). The same buffer was used for post-loading equilibrium, and FVIIa was eluted with buffer B1 (20 mmol / L sodium hydrogen phosphate hydrate, 500 mmol / L sodium chloride, pH 8.0-8.2).

[0061] The second step is S / D virus inactivation.

[0062] Triton X-100 (polyethylene glycol octylphenyl ether) and TNBP (tributyl phosphate) were added to the TMAE elution product to make the final concentrations 2% and 0.45%, respectively, and maintained at 25°C for 45 minutes to inactivate lipid enveloped viruses.

[0063] The third step is anion exchange chromatography.

[0064] The S / D virus inactivation product conductivity was adjusted to less than 12 mS / cm with buffer D (10 mmol / L tris(hydroxymethyl)aminomethane, pH 8.0-8.2). The sample was loaded onto a Q Sepharose High Performance anion chromatography column pre-equilibrated with buffer A2 (10 mmol / L tris(hydroxymethyl)aminomethane, 100 mmol / L sodium chloride, pH 8.0-8.2). The sample was loaded with the same buffer as the pre-equilibration, and then washed with buffer B2 (10 mmol / L tris(hydroxymethyl)aminomethane + 100 mmol / L sodium chloride + 2.25 mM calcium chloride solution, pH 8.0-8.2), and then eluted with eluent C1 (10 mmol / L tris(hydroxymethyl)aminomethane + 100 mmol / L sodium chloride + 5 mM calcium chloride solution, pH 8.0-8.2), and the eluent was collected.

[0065] The fourth step is hydrophobic chromatography.

[0066] The conductivity of the anion exchange chromatography eluate in the previous step was adjusted to 100 mS / cm with saturated ammonium acetate. The sample was loaded onto a Phenyl Sepharose High Performance hydrophobic chromatography column that had been pre-equilibrated with buffer A3 (10 mmol / L glycyl glycine, 1.8 mol / L ammonium acetate, pH 6.0). The sample was equilibrated after loading with the same buffer as the pre-equilibration, eluted with buffer 35% B3 (B3: 10 mmol / L glycyl glycine + 30 mmol / L trisodium citrate dihydrate, pH 6.0), and then eluted with a 10 column volume gradient of 35% to 100% B3, and the eluate was collected in sections. After RP-HPLC and SEC-HPLC purity tests, the qualified components were combined.

[0067] Step 5: Virus removal and filtration.

[0068] The washed 20 nm virus-removal filter membrane was rinsed with a hydrophobic eluent (10 mmol / L glycylglycine + 30 mmol / L trisodium citrate dihydrate, pH 6.0), and then the product obtained by hydrophobic chromatography was filtered for virus removal, and the filtration pressure was controlled at 3 bar.

[0069] Step 6: Ultrafiltration and fluid exchange.

[0070] The ultrafiltration membrane package (10 kDa) was washed with water and then balanced with a replacement buffer (10 mmol / L glycyl glycine, 40 mmol / L sodium chloride, 10 mmol / L calcium chloride, 0.5 g / L methionine, pH 6.0). The product after virus removal filtration was concentrated and replaced with a replacement buffer, and then polysorbate 80, sucrose and mannitol mother solutions were added to protect the target protein.

[0071] Step 7: Sterile filtration.

[0072] Use 0.22 μm filter membrane for sterilization filtration.

[0073] Using the above purification process, the purity of the final stock solution is shown in Table 1 below.

[0074] Table 1 Final stock solution purity table

[0075]

[0076] Example 2 Determination of polymer content

[0077] The molecular weight distribution of recombinant human coagulation factor VIIa was detected using a molecular exclusion chromatography column, and eluted using a phosphate-sodium chloride mobile phase system. The components with different molecular weights were separated according to their different retention capacities in the stationary phase matrix, and their purity was determined by peak area normalization using a UV detector. The ThermoUltimate 3000 high performance liquid chromatograph with a UV detector was used to balance the chromatographic column until the baseline was stable. The mobile phase was 50 mmol / L disodium hydrogen phosphate, 300 mmol / L sodium chloride, pH 7.5. The parameters are shown in Table 2 below.

[0078] Table 2 Gel chromatography liquid phase analysis parameters

[0079]

[0080] The results show that the size exclusion chromatography-high performance liquid chromatography method can detect that the method of the present invention can significantly remove the polymer in rFVIIa.

[0081] Example 3 Determination of oxide and degradation product content

[0082] Reverse phase chromatography column was used to detect the purity of recombinant human coagulation factor VIIa for injection. With the increase of organic phase, components with different retention capacity were eluted to achieve separation. The purity of recombinant human coagulation factor VIIa was determined by peak area normalization method through UV detector. Thermo Ultimate 3000 high performance liquid chromatograph with UV detector was used to balance the chromatographic column until the baseline was stable. Mobile phase A: 0.1% trifluoroacetic acid aqueous solution, mobile phase B: 0.1% trifluoroacetic acid acetonitrile solution. The parameters are shown in Table 3 below.

[0083] Table 3 Reversed phase chromatography liquid phase analysis parameters

[0084]

[0085]

[0086] The results show that the reverse phase chromatography-high performance liquid chromatography method can detect that the method of the present invention can significantly remove oxides and degradation products in rFVIIa.

[0087] Example 4 Determination of Gla (γ-carboxyglutamate) variants

[0088] SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to determine the Gla (γ-carboxyglutamic acid)-deficient / partially deficient variants of rFVIIa. SDS-PAGE is a denaturing polyacrylamide gel electrophoresis method based on the principle that most proteins can combine with the anionic surfactant sodium dodecyl sulfate (SDS) to form a complex by weight, so that the negative charge carried by the protein molecule far exceeds the net charge of the natural protein molecule, eliminating the charge effect of different protein molecules and separating the proteins by molecular size.

[0089] The Bio-Rad / PowerPac Basic device was used. The specific method was as follows: Place the gel in the electrophoresis tank and add the electrode buffer. Add 5 μl of molecular weight standard to the sample well of the gel, add the reference solution and the test solution to the sample well adjacent to the sample well, and cover the electrophoresis tank. Adjust the power supply voltage to 140V in the voltage regulation mode, stop the electrophoresis when the bromophenol blue migrates to the bottom of the gel. Pour out the electrode buffer, take out the gel, and stain and decolorize it.

[0090] The results of the determination according to this method are shown in the attached Figure 1 The results showed that the anion exchange chromatography in the third step of Example 1 could elute and remove Gla-deficient / partially deficient variants.

[0091] According to the contents disclosed in the present invention, although the method of the present invention has been described according to a preferred embodiment, it is apparent to those skilled in the art that the method described herein and the steps or the order of steps of the method may be changed without departing from the concept, spirit and scope of the present invention.

[0092] The disclosures of all documents cited herein are incorporated by reference, to the extent that they provide exemplary, procedural and other details supplementary to those set forth herein.

Claims

1. A method for purifying recombinant human coagulation factor VIIa, comprising the following steps performed in sequence: 1) anion exchange chromatography, wherein 1) anion exchange chromatography comprises (a) pre-equilibration, (b) post-loading equilibration, and (c) elution, The buffer used for the pre-equilibrium and post-loading equilibrium is 20% ethanol containing 50 mmol / L sodium chloride at pH 8.0-8.

2. mmol / L sodium hydrogen phosphate hydrate, the buffer used for elution is 20mmol / L sodium hydrogen phosphate hydrate containing 500mmol / L sodium chloride at pH 8.0-8.2; 2) performing S / D virus inactivation on the product obtained in step 1); 3) further purifying the product obtained in step 2) by anion exchange chromatography, wherein the anion exchange chromatography comprises (a) pre-equilibrium, (b) post-loading equilibrium, (c) washing, and (d) elution, wherein the buffer used in the pre-equilibrium and post-loading equilibrium is 10 mmol / L tris(hydroxymethyl)aminomethane containing 100 mmol / L sodium chloride at pH 8.0-8.2, the buffer used in the washing is 10 mmol / L tris(hydroxymethyl)aminomethane containing 100 mmol / L sodium chloride and 2.25 mmol / L calcium chloride at pH 8.0-8.2, and the buffer used in the elution is 10 mmol / L tris(hydroxymethyl)aminomethane containing 100 mmol / L sodium chloride and 5 mmol / L calcium chloride at pH 8.0-8.2; 4) further purifying the product obtained in step 3) by hydrophobic chromatography, wherein the hydrophobic chromatography comprises (a) adjusting the conductivity of the anion exchange chromatography eluent to 100 mS / cm with saturated ammonium acetate, (b) pre-equilibrium, (c) post-loading equilibrium, and (d) elution, wherein the buffer used in the pre-equilibrium and post-loading equilibrium is 10 mmol / L glycylglycine containing 1.8 mol / L ammonium acetate at pH 6.0, and the buffer used in the elution is 10 mmol / L glycylglycine containing 30 mmol / L trisodium citrate dihydrate at pH 6.0; 5) filtering the product obtained in step 4) to remove viruses; 6) ultrafiltration of the product obtained in step 5) to replace the liquid; 7) sterilizing and filtering the product obtained in step 6) to obtain a stock solution; The method does not comprise an affinity chromatography step.

2. The method according to claim 1, It is characterized in that The affinity chromatography is immunoaffinity chromatography in which a blood coagulation factor VIIa antibody is coupled to an affinity chromatography medium.

Citation Information

Patent Citations

  • Hydrophobic interaction chromatography purification of factor VII polypeptides

    CN101268185A

  • Purification of factor VII

    CN1121723A

  • High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant

    CN101674805A

  • Factor viia complex using an immunoglobulin fragment

    CN103025358A

  • Method used for purifying coagulation factor VIII

    CN104861060A